Table of Contents
ABOUT THIS PROFILE
- PharmaVitae Explorer database
- Chapter structure
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
- Data sourcing
EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales and growth rate performance, 2002 - 14
- Financial performance, 2002 - 14
- Merck & Co.: PharmaVitae forecasts at a glance
- Strategic insight
- Blockbuster patent expiries pose greatest threat to Merck & Co.
- Additional restructuring confirmed as Merck moves to improve operating
efficiencies
- Merck turns to merger with Schering-Plough in order to strengthen
earnings outlook
- Merck/Schering-Plough key products analysis
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- M&A activity
- Company announcements
- Future product milestones
COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- Highlights of Merck & Co.' s global restructuring plan announced in
December 2005
- M&A history
COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
- Historical analysis
- Forecast analysis
- Product analysis
- Product analysis, 2002 - 08
- Product analysis, 2008 - 14
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2008 - 14
- Core analysis, 2008 - 14
- Expiry analysis, 2008 - 14
- Launch/core/expiry configuration, 2008 - 14
- Molecule type analysis
- Externalization analysis
COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and
company-reported total sales, 2002 - 08
- Operating costs and profit analysis
- Operating costs and profit analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2008 - 14
- Operating costs and profit analysis, 2008 - 14
KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Infectious diseases
- Isentress
- Gardasil
- ProQuad/MMRII/Varivax
- Endocrine, metabolic & genetic disorders
- Cardiovascular
- Zetia/Vytorin
- Cozaar/Hyzaar
- Respiratory
- Musculoskeletal
APPENDIX
- R&D pipeline
- References
- Abbreviations
- Exchange rates
TABLES
- Table: Merck & Co. - PharmaVitae forecasts at a glance
- Table: Big Pharma peer set ranked by 2008 prescription pharmaceutical sales
- Table: Merck & Co.' s expiry portfolio
- Table: Combined pipeline of Merck & Co. and Schering-Plough (Phase III -
registration)
- Table: Merck Schering-Plough' s top 25 products in 2014, sales ($m)
- Table: Merck & Co. key product developments, Q1 - Q2 2009
- Table: Merck & Co. product deals and alliances, Q1 - Q2 2009
- Table: Merck & Co. technology deals and alliances, Q1 - Q2 2009
- Table: Merck & Co. M&A activity, Q1 2009
- Table: Merck & Co. company announcements, Q1 - Q2 2009
- Table: Merck & Co. future product milestones, 2009 - 11
- Table: Combined pipeline of Merck & Co. and Schering-Plough (Phase III -
registration)
- Table: Merck & Co. product portfolio overview ($m), 2002 - 08
- Table: Merck & Co. product portfolio overview ($m), 2008 - 14
- Table: Merck & Co. product portfolio overview ($m), 2008 - 14
- Table: Merck & Co. portfolio overview by geographic region ($m), 2008 - 14
- Table: Merck & Co. launch portfolio overview ($m), 2008 - 14
- Table: Merck & Co. core portfolio overview ($m), 2008 - 14
- Table: Merck & Co. expiry portfolio overview ($m), 2008 - 14
- Table: Merck & Co. portfolio overview by molecule type ($m), 2008 - 14
- Table: Merck & Co. portfolio overview by source ($m), 2008 - 14
- Table: Total Merck & Co. sales by business unit ($m), 2002 - 08
- Table: Merck & Co. operating revenue/cost analysis ($m), 2002 - 08
- Table: Merck & Co. operating cost ratio analysis (% of total revenues),
2002 - 08
- Table: Merck & Co. operating cost ratio analysis (% of total revenues),
2008 - 14
- Table: Merck & Co. operating revenue/cost analysis ($m), 2008 - 14
- Table: Key products overview
- Table: Isentress: overview
- Table: Isentress: sales forecast ($m), 2008 - 14
- Table: Gardasil: overview
- Table: Gardasil: sales forecast ($m), 2008 - 14
- Table: Comparative analysis of Gardasil and Cervarix
- Table: ProQuad/MMRII/Varivax: overview
- Table: ProQuad/MMRII/Varivax: sales forecast ($m), 2008 - 14
- Table: Januvia: overview
- Table: Janumet: overview
- Table: Januvia: sales forecast ($m), 2008 - 14
- Table: Janumet: sales forecast ($m), 2008 - 14
- Table: Zetia: overview
- Table: Vytorin: overview
- Table: Zetia: sales forecast ($m), 2008 - 14
- Table: Vytorin: sales forecast ($m), 2008 - 14
- Table: PV50 major dyslipidemia therapeutics, sales ($m), 2002 - 08
- Table: Cozaar/Hyzaar: overview
- Table: Cozaar/Hyzaar: sales forecast ($m), 2008 - 14
- Table: Singulair: overview
- Table: Singulair: sales forecast ($m), 2008 - 14
- Table: Fosamax: overview
- Table: Fosamax: sales forecast ($m), 2008 - 14
- Table: Merck & Co.' s R&D pipeline (Phase II - registration)
- Table: Exchange rates, 2009
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: Merck & Co. prescription pharmaceutical performance, sales ($m)
and growth rate (%), 2002 - 14
- Figure: Merck & Co.' s financial performance ($m), 2002 - 14
- Figure: Merck & Schering-Plough total prescription pharmaceutical sales
($m), 2008 - 14
- Figure: Absolute sales contribution from Merck & Schering-Plough launch
portfolios ($m), 2008 - 14
- Figure: Therapeutic focus of MRK vs MRK + SGP (% total prescription
pharmaceutical sales), 2008 - 14
- Figure: Geographic focus of MRK vs MRK + SGP (% total prescription
pharmaceutical sales), 2008 - 14
- Figure: Merck & Co. SWOT analysis
- Figure: Merck & Co. prescription pharmaceutical performance, sales ($m)
and growth rate (%), 2002 - 14
- Figure: Merck & Co. key sales growth drivers and resistors ($m), 2002 - 08
- Figure: Merck & Co. key sales growth drivers and resistors ($m), 2008 - 14
- Figure: Merck & Co. prescription pharmaceutical sales by therapy area
($m), 2002 - 14
- Figure: Merck & Co. prescription pharmaceutical sales by geographic region
($m), 2002 - 14
- Figure: Merck & Co. launch/core/expiry configuration ($m), 2008 - 14
- Figure: Merck & Co. prescription pharmaceutical sales by molecule type
($m), 2002 - 14
- Figure: Merck & Co. prescription pharmaceutical sales by source ($m), 2002
- 14
- Figure: Merck & Co. operating revenue/cost analysis ($m), 2002 - 14
- Figure: Merck & Co. operating cost ratio analysis (% of total revenues),
2002 - 14
|
Related Report
|
View Cart
